Table 2. Sentinel lymph node (SLN) compromise according to clinicopathologic subtype and size of metastasis.
| SLN+ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Clinicopathologic subtype | n | % | MAM | MM | SMM | Total | % | p* |
| Luminal A | 246 | 38.9 | 54 | 17 | 14 | 85 | 34.6 | |
| Luminal B | 243 | 38.4 | 56 | 12 | 12 | 80 | 32.9 | 0.69 |
| Luminal not specified | 70 | 11.1 | 15 | 4 | 4 | 23 | 32.9 | 0.79 |
| HER2 | 13 | 2.1 | 3 | 0 | 1 | 4 | 30.8 | 0.78 |
| Triple negative | 60 | 9.5 | 12 | 2 | 1 | 15 | 25.0 | 0.16 |
| Total | 632 | 100.0 | 140 | 35 | 32 | 207 | 32.8 | |
MAM: macrometastasis,
MM: micrometastasis,
SMM: submicrometastasis.
*
p value calculated based on chi-square test.
All profiles were compared to luminal A.